Genomic Analysis of to Explore Its Biosynthetic Potential Regarding Secondary Metabolites.

Actinomycetes have long been recognized as important sources of clinical antibiotics. However, the exploration of rare actinomycetes, despite their potential for producing bioactive molecules, has remained relatively limited compared to the extensively studied genus. The extensive investigation of species and their natural products has led to a diminished probability of discovering novel bioactive compounds from this group.

Novel Antimycin Analogues with Agricultural Antifungal Activities from the Sponge-Associated Actinomycete sp. NBU3104.

Phytopathogenic fungi could affect the growth of agricultural products and result in serious economic losses. To develop novel and potent fungicides, secondary metabolites of an oceanic mesophotic zone sp. NBU3104 was isolated by metabolomics and genomics, which led to the discovery of eight novel antimycins I-P (-), including antimycin I (), six rare acetylated actimycins J-N (-), P (), and an unusual deformylated antimycin O ().